KR100961392B1 - Production method of antibody phage display library, the antibody phage display library produced thereby and the phagemid vector comprising said antibody phage display library - Google Patents

Abstract

The present invention relates to a method for preparing an antibody phage surface presentation library, an antibody phage surface presentation library prepared by the method, a phagemid vector comprising the antibody phage surface presentation library gene, and more particularly, V _H 3-23 / V. After introducing artificial diversity into complementarity determining regions (CDRs) using the _L 1g gene as a backbone, antibody phage surface display that selects only antibody genes of appropriate sequence through genetic selection process to enhance functional diversity of the library. The present invention relates to a method for preparing a library, and the present invention provides a method for producing a human antibody library having a high diversity, and an antibody phage surface presentation library prepared by the method.

Phage surface presentation, antibody, library, beta lactamase, genetic selection

Description

Method for producing antibody phage surface presentation library, antibody phage surface presentation library prepared by the above method, phagemid vector comprising the antibody phage surface presentation library gene, TECHNICAL METHOD OF ANTIBODY PHAGE DISPLAY LIBRARY, THE ANTIBODY PHAGE DISPLAY LIBRARY PRODUCED THEREBY AND THE PHAGEMID VECTOR COMPRISING SAID ANTIBODY PHAGE DISPLAY LIBRARY}

The present invention relates to a method for preparing an antibody phage surface presentation library, an antibody phage surface presentation library prepared by the method, and a phagemid vector comprising the antibody phage surface presentation library gene, and more specifically, screening by a genetic selection technique. The present invention relates to a method for preparing a single-chain fragment antibody phage surface presentation library having improved functional diversity and an antibody phage surface presentation library prepared by the method, and a phagemid vector comprising the antibody phage surface presentation library gene.

Phage display is a technique that genetically manipulates bacteriophage, a bacterial host, so that genotypes (genes) and phenotypes (proteins) are linked through a single phage particle. In this case, the gene as a genotype is inserted as part of a phage gene, and the protein as a phenotype is presented on the surface of the phage particle containing the gene of the protein. These physical combinations of genotypes and phenotypes are very important concepts in protein engineering, and their phenotypic properties make it easy to obtain, clone, amplify, analyze and manipulate the genes of a selected protein clone.

Antibodies are particularly useful examples of phage surface presentation techniques. By presenting an antibody library having a very high diversity on the surface of the phage and binding to the surface-adsorbed antigen, it is possible to obtain genes of antibody clones that selectively bind to the antigen. This is a very effective method of obtaining antibodies without going through an experimental animal, and in particular, since human antibodies to any antigen can be obtained, they have very high utility in the development of new therapeutic antibodies and the like with less immune response in the human body. In order to obtain a good antibody having a high binding affinity, the quality of the library is important, especially the size and functional diversity of the library and the quality of the clone.

The size of the library is one of the most important factors in determining the quality of the antibody selected therefrom. The antigen binding site of the antibody library theoretically has a random diversity that is not mild to any particular antigen, and antibodies that selectively bind to specific antigens by pure chance occur in random diversity. Therefore, as the size of the library increases, ie, the number of different antibodies in the library increases, the probability of finding antibodies with high selectivity and affinity by chance increases. In general, it is recognized that a minimum size of 10 ⁸ or more is required, and a large number of antibody libraries have sizes of 10 ^{9-10 11} .

The functional diversity of the library is the proportion of the clones that actually express the antibody among the clones that make up the library. Even if the size of the library is large, if the functional diversity is low, the actual library size is reduced. The lack of functional diversity is largely due to errors in DNA synthesis and amplification during library construction. Antibody libraries are constructed through multiple stages of polymerase chain reaction (PCR), which inevitably leads to low frequency errors due to the nature of enzymes and reactions, and when these errors accumulate, functional diversity of the final library is reduced. Also, especially in synthetic libraries, errors are more likely to be introduced due to efficiency problems of base synthesis. As such, the problem of functional diversity tends to be particularly prominent in synthetic libraries, and most synthetic libraries require design considerations to avoid these problems.

The quality of the individual clones that make up the library, ie expression and stability and immunogenicity, is also one of the factors that determine the performance of the antibody library. These factors must be considered from the design stage of the synthetic antibody library in order to select an antibody engineering clone. In particular, in the step of introducing artificial diversity into the existing antibody genes, the resulting diversity should be designed to have compatibility with the antibody backbone, and the rapid change from the amino acid sequence of the natural antibody may result from the artificial synthetic antibody. There is a risk of impairing the suitability and stability. Therefore, techniques for efficiently mimicking natural diversity have been reported when designing artificial diversity (Lee, C. V. et al. Journal of Molecular Biology, 2004, 340, 1073-1093).

In order to construct a synthetic library, the design of the library sequence must be preceded. Unlike B cell-derived antibody libraries or natural antibody libraries with relatively high skeletal diversity, synthetic antibody libraries are constructed based on one or a limited number of skeletal sequences. However, in the synthetic antibody library, mutation and base addition / deletion frequently occur due to an error in the chemical synthesis process, and thus functional diversity (a ratio of clones capable of expressing normal antibodies among all clones) is lowered.

Accordingly, the technical problem to be achieved by the present invention is to provide a synthetic library having a high functional diversity, a synthetic library prepared by the method, and a phagemid vector including the library gene.

In order to achieve the above technical problem, the present invention provides a method for producing an antibody phage surface presentation library that imparts artificial diversity to complementarity determining regions (CDR) by using the V _H 3-23 / V _L 1g gene as a skeleton (Iii) preparing a pFDV plasmid vector by introducing restriction enzyme cleavage sequences immediately after the leader sequence of the beta lactamase gene in a plasmid vector having the beta lactamase gene as a selection marker; Ii) cleaving a pFDV plasmid vector using said restriction enzyme; Iii) inserting the scFv gene library between the cleaved pFDV vectors consisting of AE, BE, CF, and DF sub-libraries obtained through serial polymerization as shown in Table 2 and each having the nucleotide sequence or amino acid sequence of FIG. 2; Iii) transforming the pFDV vector containing the scFv gene library into a host strain and culturing in a medium containing antibiotics; v) separating and purifying the pFDV plasmid vector including the scFv gene library after culture; Iii) transplanting CDR-H3 by polymerase chain reaction with oligonucleotides of Table 1 as primers using pFDV plasmid vector containing the isolated and purified scFv gene library, and iii) grafting the CDR-H3. Provided are a method for preparing an antibody phage surface presentation library comprising cutting and ligating an scFv library gene and a pComb3X vector with a restriction enzyme, transforming and culturing the host strain.

The present invention also provides a method for producing an antibody phage surface presentation library, wherein the restriction enzyme is SfiI.

The present invention also provides an antibody phage surface presentation library prepared by the method for producing an antibody phage surface presentation library.

In addition, the present invention provides a method for producing an antibody phage surface presentation library, wherein the plasmid vector having the beta lactamase gene as a selection marker is a pET17b plasmid vector.

The present invention also provides a phagemid vector combination in which the pComb3X vector is inserted with a scFv gene library composed of AE, BE, CF, and DF sublibrary each having the nucleotide sequence or amino acid sequence of FIG. 2.

In addition, the present invention provides a bacteriophage (Accession No .: KCCM10938P) including a phagemid vector having a scFv gene library composed of AE, BE, CF, and DF sublibrary having a nucleotide sequence or amino acid sequence of FIG. 2 in a pComb3X vector, respectively. do.

The present invention can provide a high quality synthetic human antibody library with high functional diversity through an efficient and fast process and a method of manufacturing the same.

Hereinafter, the present invention will be described in more detail with reference to the accompanying drawings.

A. Definition

The phage display manipulates the genes of the M13 bacteriophage to fuse the foreign protein gene to one of the surface proteins, and the external protein is fused to the surface protein of the produced phage and presented on the surface of the phage. Is a technique. Surface presentation of proteins often fuses exogenous genes to the 5 'side of the gIII gene.

An "antibody" is a glycoprotein that specifically binds to a target antigen. Heterotetramer consists of two light chains and two heavy chains. Each chain consists of a variable domain with a variable amino acid sequence and a constant domain having a constant sequence. . The antigen binding site is located at the tertiary end of the variable domain, which is formed by the collection of complementarity determining regions, each of which is present in the light and heavy chains. Complementarity determining regions are particularly highly variable regions of amino acid sequences among the variable domains, and these high variability allows specific antibodies to be found against various antigens.

"Immune globulin" is a concept including antibody-like molecules and antibodies having the same structural characteristics as antibodies and having no antigen specificity.

A "single-chain Fv" (scFv) is a protein that connects the variable domains of the light and heavy chains of an antibody with a linker consisting of peptide chains of about 15 amino acids. Light chain variable domains-linking sites-heavy chain variable domains, or heavy chain variable domains-linking sites-light chain variable domains can be in any order and have the same or similar antigenicity as the original antibody. The linking site is a hydrophilic, flexible peptide chain composed mainly of glycine and serine, and 15 amino acid sequences or similar sequences of "(Gly-Gly-Gly-Gly-Ser) ₃ " are mainly used.

An "antibody library" is a collection of various antibody genes with different sequences. Very high diversity is required to isolate antibodies specific for any antigen from the antibody library, and libraries of 10 ^{9-10 11} different antibody clones are generally constructed and used. The antibody gene constituting such an antibody library is cloned into a phagemid vector and transformed into E. coli.

A "phagemid" vector is a plasmid DNA having a phage origin of replication. Typically, the antibiotic resistance gene has a selection marker. The phagemid vector used for phage surface expression includes the gIII gene of M13 phage or a part thereof, and the library gene is ligated at the 5 'end of the gIII gene to be expressed as a fusion protein in E. coli. The pComb3X vector used in the present invention is an example of a phagemid vector.

A "helper phage" is a phage that provides the genetic information needed for phagemids to be assembled into phage particles. Since phagemid contains only gIII or a part of phage gene, E. coli transformed with phagemid is infected with an auxiliary phage to supply the remaining phage gene. There are M13K07 or VCSM13, and most of them contain antibiotic resistance genes such as kanamycin, which allows you to select E. coli infected with auxiliary phage. In addition, since there is a defect in the packaging signal, the phagemid gene is selectively assembled into the phage particle rather than the auxiliary phage gene.

"Beta lactamase" is an enzyme that confers antibiotic resistance by degrading beta-lactam antibiotics such as penicillin, ampicillin and carbenicillin.

A "leader sequence" is a nucleotide sequence or amino acid sequence which is located at the 5 'end of a gene and functions as a signal required when a protein expressed from the gene is secreted to the outside.

The notation of a base is as follows. A = adenine; T = thymine; G = guanine; C = cytosine; M = A or C; R = A or G; S = C or G; W = A or T; Y = C or T; K = G or T; B = C, G or T; D = A, G, or T; H = A, C or T; V = A, C or G, N = A, T, G or C.

B. Design, Build, and Validate Your Library

The methods described herein can be used to construct human antibody libraries and from which human antibodies to any antigen can be obtained. Antibody libraries can be constructed by obtaining their diversity from B cells contained in bone marrow, spleen, blood, etc., and by obtaining diversity through artificial design and synthesis. The present invention describes the construction and validation of synthetic human antibody libraries. do.

Phage surface-presenting antibody libraries are constructed in the form of Fab or scFv fragments that are part of an immunoglobulin molecule. Because these fragments are smaller than immunoglobulins of 150 kDa size, they allow for the efficiency of protein engineering manipulations and have the same antigen selectivity as immunoglobulin molecules. In the present invention, a library using a scFv fragment having a size of 25 kDa was constructed. Specifically, the V _H domain and the V _L domain of an immunoglobulin were chained with 15 amino acids, that is, (Gly-Gly-Gly-Gly-Ser) ₃ . One polypeptide chain that is linked.

In order to construct a synthetic library, the design of the library sequence must be preceded. Unlike B cell-derived antibody libraries or natural antibody libraries with relatively high skeletal diversity, synthetic antibody libraries are constructed based on one or a limited number of skeletal sequences. The antibody library produced through the present invention has one skeleton. Specifically, all clones constituting the library have the V _H 3-23 gene and the V _L 1g gene of human immunoglobulin as a backbone, and the library was constructed by introducing artificial diversity into the complementarity determining region.

The construction of the library was accomplished by combining the oligonucleotides shown in Table 1 as shown in Figure 1 via polymerase chain reaction. Table 1 below is a list of DNA oligonucleotides used to construct the antibody phage surface presentation library of the present invention.

Name / number Sequence Oligonucleotides for Skeletal Site Synthesis FR-H1-f One GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTG FR-H1-b 2 GCTAAAGGTGAATCCAGAGGCTGCACAGGAGAGTCTCAGGGACCCCCCAGGCTG FR-H2-b 3 TGAGACCCACTCCAGCCCCTTCCCTGGAGCCTGGCGGACCCA FR-H3-b 4 GGCTGTTCATTTGCAGATACAGCGTGTTCTTGGAATTGTCTCTGGAGATGGTGAACCG FR-H3-f 5 GTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCCGTGTATTACTGTGCG JH-15-f 6 TTCGACTACTGGGGCCAGGGTACACTGGTCACCGTGAGCTCA JH-6-f 7 ATGGACTGCTGGGGCCAGGGTACACTGGTCACCGTGAGCTCA FR-L1-f 8 CAGTCTGTGCTGACTCAGCCACCCTCAGCGTCTGGGACCCCC FR-L1-b 9 ACAAGAGATGGTGACCCTCTGCCCGGGGGTCCCAGACGCTGAG FR-L2-b 10 ATAGATGAGGAGTTTGGGGGCCGTTCCTGGGAGCTGCTGGTACCAG FR-L3-b 11 GATGGCCAGGGAGGCTGAGGTGCCAGACTTGGAGCCAGAGAATCGGTCAGGGACCCC FR-L3-f 12 TCAGCCTCCCTGGCCATCAGTGGGCTCCGGTCCGAGGATGAGGCTGATTATTACTGTG JL-f 13 TATGTCTTCGGCGGAGGCACCAAGCTGACGGTCCTAGGC FRH3-short-b 14 CGCACAGTAATACACGGCC JH15-short-f 15 TTCGACTACTGGGGCCAG JH6-short-f 16 ATGGACGTCTGGGGCCAGGGTACACTG pC3X-f 17 GCACGACAGGTTTCCCGAC pC3X-b 18 AACCATCGATAGCAGCACCG H1-b 19 GCTAAAGGTGAATCCAGAG H2-f 20 CTGGGTCCGCCAGGCTCCAG H2-b 21 TGAGACCCACTCCAGCCC H3-f 22 CGGTTCACCATCTCCAGAG L1-b 23 CAAGAGATGGTGACCCTC L2-f 24 CTGGTACCAGCAGCTCCCAG L2-b 25 ATAGATGAGGAGTTTGGG L3-f 26 GGGGTCCCTGACCGATTC L3-b 27 CACAGTAATAATCAGCCTC JL-short-f 28 TATGTCTTCGGCGGAGGC Oligonucleotides for Synthesis of Complementarity Determinants CDR-H1-f 29 CTCTGGATTCACCTTTAGCRRTTATKMTATGAGCTGGGTCCGCCAGGCTCCAG CDR-H2-f 30 GGGCTGGAGTGGGTCTCAKBGATCTMTYMTRRTRRTRGTARTAHATATTACGCTGATTCTGTAAAAGGTCGGTTCACCATCTCCAGAG CDR-H3-9-b 31 CTGGCCCCAGTAGTCGAAMNNMNNMNNMNNTYTCGCACAGTAATACACGGC CDR-H3-14-b 32 CTGGCCCCAGTAGTCGAAMNNMNNMNNMNNMNNMNNMNNAVSAYCTYTCGCACAGTAATACACGGC CDR-H3-20-b 33 CTGGCCCCAGACGTCCATASCATHAKMAKAAKAMNNMNNMNNMNNMNNMNNMNNAMBAVBANVTYTCGCACAGTAATACACGGC CDR-H3-20SS-b 34 CTGGCCCCAGACGTCCATASCATHAKMAKAAKAACAMNNMNNMNNMNNACAMNNAMBAVBANCTYTCGCACAGTAATACACGGC CDR-L1-f 35 GAGGGTCACCATCTCTTGTASTGGCTCTTCATCTAATATTGGCARTAATDMTGTCWMCTGGTACCAGCAGCTCCCAG CDR-L2-f 36 CCCAAACTCCTCATCTATKMTRATARTMAKCGGCCAAGCGGGGTCCCTGACCGATTC CDR-L3-b 37 GAGGCTGATTATTACTGTGSTDCTTGGGATKMTAGCCTGARTGSTTATGTCTTCGGCGGAGGC Oligonucleotides for V _H -V _L Binding Sites linker-b 38 CTGAGTCAGCACAGACTGCGATCCGCCACCGCCGGATCCACCTCCGCCTGAACCGCCTCCACCTGAGCTCACGGTGACCAG Oligonucleotides for Single Chain Monoclonal Antibody Amplification VH-f 39 AATTCGGCCCAGGCGGCCGAGGTGCAGCTGTTGGAG VL-b 40 TTAAGGGCCGGCCTGGCCTAGGACCGTCAGCTTG pET-bla-f 41 AAATGTGCGCGGAACCCC pET-bla-b 42 CCCACTCGTGCACCCAAC VH-short-f 43 AATTCGGCCCAGGCGGCC VL-short-b 44 TTAAGGGCCGGCCTGGCC Oligonucleotides for introducing SfiI restriction enzyme cleavage sequences into the pET17b vector bla-f 45 GAGGAGGAGGAGGGCCGCCTGGGCCAGGCAAAATGCCGCAAAAAAGG bla-b 46 GAGGAGGAGGAGGGCCAGGCCGGCCAGCACCCAGAAACGCTGGTG Oligonucleotides for Sequencing ompseq 47 AAGACAGCTATCGCGATTGCAG

Oligonucleotides corresponding to six complementarity determining sites were prepared by randomizing some base positions in the synthesis step. As a result of this randomization, artificial diversity was introduced into the library. Since five complementarity determining regions, except for CDR-H3, introduced limited randomization that mimics the diversity of human antibody genes (Lee et al. Journal of Molecular Biology 2004, 340, 1073-1093), the diversity derived from this is natural. It is expected to be similar to the diversity of human antibodies produced in the human body. For example, KMT (K = G or T, M = A or C) among the restricted randomized codons is a mixed codon of GCT, GAT, TCT, TAT and represents four amino acids, Ala, Asp, Ser, and Tyr. If the above four amino acids or a portion thereof is frequently observed at a specific position of, the sequence of the natural antibody can be mimicked by introducing a KMT codon. Specific examples are as in Example 1 below.

Example 1 (Preparation of single chain fragment antibody clone by polymerase chain reaction)

Mix oligonucleotides as shown in FIG. Two mixtures are required, one oligonucleotide (43, 39, 1, 2, 29, 3, 30, 4, 5, 14) is mixed and the other oligonucleotide (15, 6, 38, 8, 9) , 35, 10, 36, 11, 12, 37, 13, 40, 44) are mixed. These are referred to as V _H fragments and J _H -V _L fragments, respectively. The concentration of each oligonucleotide in the final reaction mixture is 12.5 nM and the concentration of the outermost oligonucleotides (Table 1 and 43, 14, 15, 44 in Figure 1) is 600 nM. To this, polymerase (Taq) buffer, polymerase and dNTP 0.8mM are added, and nuclease-free water is added so that the total volume is 100 microliters. The above mixture is subjected to the polymerase chain reaction by the following program. 94 ^o C, 2 minutes; (94 ^o C, 30 sec-54 ^o C, 30 sec-72 ^o C, 90 sec) 30 repetitions; 72 ^o C, 10 minutes. The reaction is electrophoretically separated on a 1% agarose gel and then extracted and purified from the gel. Using the purified V _H fragment as a template, oligonucleotides 43 and 31 were further purified using a polymerase chain reaction in the same program as above. This is called the V _H -CDRH3 fragment. The V _H -CDRH3 fragment and J _H -V _H fragment were used as templates, and 43 and 44 oligonucleotides were used as primers to amplify and purify the polymerase chain reaction using the same program as above to obtain a single-chain fragment antibody gene. This was digested with SfiI restriction enzymes and then ligated into pComb3X vectors (Scott and Barbas III, 2000, Phage display vectors, In: Phage Display Laboratory Manual, 1st ed. Cold Spring Harbor Laboratory Press, NY, USA, pp. 2.1-2.19). And cultured in a medium containing carbenicillin by transforming into ER2537 Escherichia coli.

As described above, single-chain fragment antibody clones obtained through the combination of oligonucleotides frequently generate mutations and base additions / deletions due to errors in the chemical synthesis process of oligonucleotides, and thus functional diversity (which may express normal antibodies among the clones). The percentage of clones that can be lowered. In order to reduce this effect, mutation-free clones (called M-) selected through sequencing among the clones were used as templates, and the mutation-free library was reconstructed through polymerase chain reaction. Table 2 below is a list of polymerase chain reactions for removing mutations from single chain fragment antibody libraries.

Polymerase Chain Reaction Template result Forward primer number (Table 1) Reverse primer number (Table 1) M- #One 20 18 M- #2 22 18 M- # 5 24 18 M- # 6 26 18 M- # 7 28 18 M- a 17 19 M- b 17 23 M- c 17 23 #One d 29 18 #2 e 30 18 # 5 f 35 18 # 6 g 36 18 # 7 h 37 18 a + d ad 17 21 b + f bf 17 25 c + f cf 17 25 ad + e ade 17 14 ade A 17 31 ade B 17 32 ade C 17 33 ade D 17 34 bf + g bfg 17 27 cf + g cfg 17 27 bfg + h E 15 18 cfg + h F 16 18 A + E AE 17 18 B + E BE 17 18 C + F CF 17 18 D + F DF 17 18

"Polymerase Chain Reaction Template" in Table 2 refers to a DNA fragment used as a template, and "Product" refers to a DNA fragment obtained by amplification from the polymerase chain reaction. "Forward primer" and "reverse primer" refer to oligonucleotides having sequences capable of complementarily binding to the sequences of the 5 'and 3' terminal portions of the polymerase chain reaction product, respectively, and are used as primers of the polymerase chain reaction. It became. Specific polymerization reaction is the same as in Example 2.

Example 2 (Library Synthesis)

The polymerase chain reaction was performed using primers shown in Table 2 using M- as a template. The reaction program was 94 ^° C., 2 minutes; (94 ^o C, 30 sec-54 ^o C, 30 sec-72 ^o C, 90 sec) 30 repetitions; 72 ^o C, 10 minutes. The DNA fragments resulting from therefrom # 1, # 2, # 3 , # 5, # 7, a, b, c were respectively separated, extracted, purified by 1% agarose gel electrophoresis. Next, the polymerase chain reaction was carried out in the same manner as above using the primers shown in Table 2 as the template using # 1, # 2, # 3, # 6, and # 7 DNA fragments, and the result was purified by agarose gel electrophoresis. DNA fragments d, e, f, g and h were obtained. In addition, an overlap extension PCR using a and d, b, f, c and f, which are pairs of DNA fragments having a complementary sequence at the 3 'end, as a template, respectively, was carried out using the primers described in Table 2. DNA fragments ad, bf, and cf were obtained in the same manner as above, and purified by agarose gel electrophoresis. Continuously ad and e, bf and g, cf and g as a template through the above-expanded polymerase chain reaction ade, bfg, cfg was obtained by using the primers shown in Table 2. DNA fragments A, B, C, and D were obtained through polymerase chain reaction using ade as a template and the primers described in Table 2 were purified by agarose gel electrophoresis. bfg and cfg were purified by agarose gel electrophoresis to obtain E and F, respectively, through polymerase chain reaction using the primers listed in Table 2 as a template. Subsequently, A and E, B and E, C and F, D, and F were used as templates to obtain single chain fragment antibody genes AE, BE, CF, and DF using the primers shown in Table 2 through the double-extension polymerase chain reaction. Purified by agarose gel electrophoresis. This was digested with SfiI restriction enzyme, ligated to pComb3X vector, transformed into ER2537 Escherichia coli, and cultured in a medium containing carbenicillin.

The CDR-H3 region of the natural antibody has a very high diversity due to the antibody production mechanism of the immune system, and in order to mimic this, unlimited randomization was introduced into this region in this library by the method described above. Specifically, an NNK codon was inserted at a portion of the CDR-H3 moiety, and 32 individual codons derived therefrom may represent all 20 amino acids and one stop codon. Indeed, oligonucleotides representing the CDR-H3 moiety consist of some restriction randomization codons and an unlimited number of randomization codons adjacent thereto. One of the factors that determine the antigenic selectivity of antibodies is the length of the CDR-H3 region (Collis et al. Journal of Molecular Biology 2003, 325, 337-354) and four different lengths of CDR-H3 to reflect this. The site was designed. The Kabat definition of the sequence of immunoglobulins states that they have 9, 14, and 20 CDR-H3 residues, respectively, and CDR-H3, which has 20 residues, is in turn a disulfide bond formed by two cysteine residues. Are divided into those that do not have) and those that have. Disulfide bonds serve to impart structural stability to the liver CDR-H3 sites. These were designated as AE, BE, CF, and DF sublibrary, respectively, as described in the experimental method above. The base sequence and amino acid sequence of the constructed library are summarized in FIG.

The scFv gene library combined with the above method has accumulated problems in the process of synthesizing oligonucleotides corresponding to the complementarity determining sites, causing most of the clones to have sequence problems, and as a result, they fail to express scFv fragments and functional diversity. Will be very low. Analysis of phage ELISA revealed that only 30% or less of the clones expressed and presented scFv, which significantly reduced the quality of the library. To overcome this, the primary library was screened through genetic selection. Specifically, the pET17b plasmid vector was manipulated to introduce two SfiI restriction enzyme cleavage sequences between the beta lactamase gene and the leader sequence, which is a secretion signal of beta lactamase, and the vector derived therefrom was named pFDV ( 3 and 4). The scFv gene library prepared above was inserted into the pFDV vector, transformed into the TOP10F 'Escherichia coli strain, and applied to agar medium containing carbenicillin antibiotics. In this case, a clone that is not expressed because of an abnormality in the scFv gene does not express a beta lactamase gene fused to the scFv gene, and thus cannot be grown in a medium containing carbenicillin. In this way only scFv-expressing clones could be selected, yielding about 10 ⁷ transformed E. coli colonies. A specific method is as in Example 3 below.

Example 3 (Library Inspection)

Polymerase chain reaction using oligonucleotides 45 and 46 of Table 1 as a primer and pET17b vector as a template (94 ^o C, 2 min; (94 ^o C, 30 sec-54 ^o C, 30 sec-72 ^o C, 3 Min) 20 repetitions; 72 ^° C., 10 min), and the resultant was purified by agarose gel electrophoresis. The above results and the previously purified BE fragments were digested with SfiI restriction enzymes, ligated, transformed into TOP10F 'Escherichia coli, and incubated on agarose medium containing carbenicillin. A single colony was taken and cultured under stirring in a medium containing carbenicillin, and then plasmids were separated and purified from the grown E. coli cells, which were termed pFDV. After cutting the pFDV vector, AE, BE, CF, and DF fragments with SfiI restriction enzymes, each of the fragments was ligated with the cleaved pFDV vector, transformed into E. coli TOP10F ', and then agarose medium containing carbenicillin. The cells were coated and cultured to obtain 10 ⁷ transformed E. coli colonies.

Since the diversity of 10 ⁷ obtained by this method is low compared to the size of the library required for efficient antibody discovery, the diversity of the CDR-H3 region was implanted here again (FIG. 5). Functional diversity is expected to decrease due to errors in the synthesis of oligonucleotides corresponding to the CDR-H3 site, but the overall diversity is more effective, and consequently, the quality of the library is expected to be improved. Various scFv gene libraries made in this way were digested with SfiI restriction enzymes and inserted into pComb3X vectors (Scott and Barbas III, 2000, Phage display vectors, In: Phage Display Laboratory Manual, 1st ed. Cold Spring Harbor Laboratory Press, NY , USA, pp. 2.1-2.19). After transforming to the ER2537 Escherichia coli strain, a library having a total size of 7.6 × 10 ⁹ was obtained. The specific method is the same as Example 4 below, and is summarized in FIG.

Example 4 (Giving Library Diversity)

PFDV plasmid containing the AE and BE library genes obtained in Example 3 was used as a template, and oligonucleotides 41, 14, 15, and 42 in Table 1 were respectively used as a pair of primers, respectively. Got it. Similarly, pFDV plasmids containing CF and DF library genes were used as templates, resulting in two DNA fragments resulting from primer pairs 41, 14 and 16 and 42, respectively. Four DNA fragments from pairs 41 and 14 (with AE, BE, CF, and DF as templates, respectively) were used as templates for 41 and 31 (AE), 41 and 32 (BE), and 41 33 (CF), 41 and 34 (DF) were subjected to polymerase chain reaction with primer pairs to obtain DNA fragments, which were purified by agarose gel electrophoresis. The above DNA fragments and DNA fragments obtained from primer pairs 15/42 (AE, BE) or DNA fragments obtained from pairs 16/42 (CF, DF) were used as templates for the expansion of the polymerase chain reaction. Using the No. and No. 42 as a primer, a single chain fragment antibody library gene was obtained and purified by agarose gel electrophoresis. The above gene and pComb3X vector were digested with SfiI restriction enzyme, ligated, transformed into ER2537 Escherichia coli, and cultured in a medium containing carbenicillin and 2% glucose.

The final library is a mix of four sub-libraries with different CDR-H3 lengths, each sub-library is 2.1 x 10 ⁹ (AE), 2.7 x 10 ⁹ (BE), 1.1 x 10 ⁹ (CF), It has 1.7 x 10 ⁹ (DF) clones. These libraries were analyzed by sequencing and phage ELISA. 6 and 7 are phage ELISA analysis results (FIG. 6) and sequencing results (FIG. 7) of the surface-presenting antibody library of the present invention, respectively. Phage ELISA used a method of capturing the expressed phage antibody clone on the surface through anti-HA antibody and then detecting it through horseradish peroxidase (HRP) -anti-HA antibody and tetramethylbenzidine (TMB) substrate. From this it was verified that 70-80 percent of the clones expressed scFv and presented it on the phage surface.

The transformed E. coli library was infected with VCSM13 helper phage to obtain an antibody phage library with scFv clones (Rader, Steinberger and Barbas III, 2000, Phage display vectors, In: Phage Display Laboratory Manual, 1st ed). Cold Spring Harbor Laboratory Press, NY, USA, pp. 10.7-10.9), which was deposited with the Korea Microbiological Conservation Center in accordance with the Budapest Treaty (Accession No .: KCCM10938P). This library contains more than 10 ¹² colony forming units (CFUs) per milliliter to obtain more phage libraries by re-infecting and amplifying E. coli hosts or converting them into E. coli or phagemid-type libraries. (Rader, Steinberger and Barbas III, 2000, Phage display vectors, In: Phage Display Laboratory Manual, 1st ed. Cold Spring Harbor Laboratory Press, NY, USA, pp. 10.10-10.11). Through this experiment to select antigen-specific antibodies against a variety of antigens to verify the functionality of the antibody phage library as follows. Peroxiredoxin 2 (PrxII) is one of the proteins that has antioxidant activity in cells. Using this as an antigen, a panning experiment was performed to select antibodies that selectively bind to PrxII.

Example 1

A 10 μg / ml PrxII solution was added to the immunotube to adsorb proteins on the surface of the test tube for 1 hour, and then a 3% solution of powdered milk was added to the test tube to protect the surface where PrxII was not adsorbed. After emptying the test tube was added to the antibody phage library of 10 ¹² CFU dispersed in a powdered milk 3% solution to bind to the antigen. Nonspecifically bound phages were washed three times with TBST (tris buffered saline-tween20) solution, and the remaining antigen-specific phage antibodies were eluted with 100 mM triethylamine solution. The eluted phage was neutralized with 1.0M Tris-HCl buffer (pH 7.8) and then infected with ER2537 Escherichia coli at 37 ° C for 1 hour, and the infected E. coli was applied to LB (Luria-Bertani) agar medium containing carbenicillin. Incubated at 37 degrees. E. coli cultured the next day was suspended in 3 mL of super broth (SB) -carbenicillin culture, 15% glycerol was added to store some at -80 ^o C, and 50 microliters of the remaining 20 mL of SB-carbeni It was inoculated in silin-2% glucose solution and incubated at 37 degrees. When the absorbance of the 600 nanometer light of the culture medium is 0.5, only the bacteria are separated by centrifugation, and suspended again in 20 mL of SB-carbenicillin culture medium, and then added with 10 ¹² PFU (plaque forming unit) VCSM13 auxiliary phage. Incubated at 37 degrees with stirring. After 1 hour 70 μg / ml of kanamycin was added and incubated overnight with rapid stirring at 250 ° C. (250 rpm). The next day, after centrifuging the culture, antigen-specific clones were concentrated by repeating the panning process using 1 mL of the supernatant containing phage particles as a library.

After repeated panning about 3-4 times, E. coli containing the antibody gene was applied to LB agar medium containing carbenicillin and cultured to obtain single colonies, which were inoculated and cultured in 200 μL SB-carbenicillin solution. It was then induced by IPTG to express the scFv protein in E. coli periplasm (periplasm). E. coli was suspended in 100 μL of a borate-buffered saline (BBS) solution and stirred at 4 ° C. overnight to extract periplasm, which was used to confirm the binding of the PrxII antigen to the scFv using the ELISA technique (Steinberger). , Rader and Barbas III, 2000, Phage display vectors, In: Phage Display Laboratory Manual, 1st ed. Cold Spring Harbor Laboratory Press, NY, USA, pp. 11.9-11.12). Bound scFv was detected using horseradish peroxidase (HRP) -anti-HA antibody and tetramethylbenzidine (TMB) substrate. Antigen-specific antibody clones identified therefrom were analyzed by sequencing. The number and sequence analysis results of the antigen-specific antibodies obtained therefrom are shown in Table 3.

Use Example 2-5

In a similar manner, antibody discovery experiments were performed for sulfiredoxin protein and four additional antigens, including insulin, glutathione, and LIME peptide (Hur et al. Journal of Experimental Medicine, 2003, 198, 1463-1473). Was performed. Sulpyredoxin and insulin proceeded in the same way as peroxyredoxin 2, and the 9-amino acid LIME peptide binds to bovine serum albumin (BSA) using ethylcyclohexylcarbodiimide (EDC). After proceeding in the same manner. For glutathione consisting of three amino acids, a short peptide with the sequence Xaa-Xaa-Xaa-Cys-Xaa-Xaa-Xaa-Lys-biotin containing biotin and cysteine (Xaa = 19 amino acids except cysteine Randomly included position) was used to connect the peptide and glutathione through the disulfide bond after binding to the magnetic particles (magnetic bead) streptavidin-bound. In this case, the antigen is immobilized on the magnetic particle surface, not on the immunoassay surface. Table 3 shows the number and sequence analysis of the antibodies obtained for the various target antigens through the above experiment. It was possible to select a plurality of antigen-specific antibody clones evenly against various antigens having various sizes.

Among them, two antibody clones against peroxyredoxin 2 were used to express and purify a single-chain fragment antibody (single-chain Fv, scFv) to analyze the expression and functionality of the selected antibody clones. The pComb3X plasmid containing the antibody gene was obtained from an E. coli clone, and then transformed into the TOP10F 'Escherichia coli and applied to LB-carbenicillin agar plates. From this, a single colony was obtained and inoculated in 4 mL of SB-carbenicillin solution, and the culture was stirred overnight at 37 ° C. This was added again to 400 mL of SB-carbenicillin-2% glucose culture, incubated until OD600 = 0.5, followed by centrifugation, and the precipitated E. coli was suspended in 400 mL of SB-carbenicillin. IPTG was added thereto at a concentration of 1 mM to induce antibody expression and incubated at 30 degrees for 4 hours. The culture solution was centrifuged to suspend E. coli in 20 mL of BBS buffer (borate buffered saline; 200 mM sodium borate, 150 mM NaCl, 2 mM EDTA, pH 8.0) and stirred slowly at 4 degrees overnight. The next day after centrifugation the supernatant was taken and 5 mM MgCl ₂ was added. 0.5 mL of Ni-NTA agarose suspension was added thereto and then slowly rotated at 4 degrees for 1 hour. This was added to a column (Bio-rad Polyprep or similar) to isolate the antibody-bound agarose particles and washed by adding 20 mL of PBS buffer containing 5 mM imidazole to the column. Again, 1 mL of PBS buffer (pH 7.4) containing 200 mM imidazole was added to elute the antibody from the agarose particles. The purified single-chain fragment antibody was measured and analyzed for purity and purification amount using SDS-PAGE electrophoresis (see FIG. 8). Single chain fragment antibodies could be purified with yields of up to 1 milligram per liter of culture with about 80% purity.

One embodiment of the present invention described above should not be construed as limiting the technical spirit of the present invention. The protection scope of the present invention is limited only by the matters described in the claims, and those skilled in the art can change and change the technical idea of the present invention in various forms. Therefore, such improvements and modifications will fall within the protection scope of the present invention, as will be apparent to those skilled in the art.

1 is a schematic diagram showing the construction of a single-chain fragment antibody library from oligonucleotides (number is oligonucleotide number of Table 1)

2 is a nucleotide sequence and amino acid sequence of the library of the present invention

Figure 3 is an understanding of the manipulation of the pET17b vector to enhance the functional diversity and cloning of the single-chain fragment antibody library

4 is a nucleotide sequence of the pFDV vector of the present invention produced by the method shown in FIG.

Figure 5 is an understanding of the process of grafting CDR-H3 into the single-chain fragment antibody sequence of the present invention and the construction of the final library

6 shows the results of phage ELISA analysis of the surface-presenting antibody library of the present invention

Figure 7 shows the sequencing results of the surface-presenting antibody library of the present invention

8 is polyacrylamide gel electrophoresis (Coomassie staining) of purified single chain fragment antibody. 1: marker, 2, 4, 6, 8: E. coli extract before purification, 3, 5, 7, 9: purified single chain fragment antibody

<110> Ewha University-Industry Collaboration Foundation <120> PRODUCTION METHOD OF ANTIBODY PHAGE DISPLAY LIBRARY, THE ANTIBODY          PHAGE DISPLAY LIBRARY PRODUCED THEREBY AND THE PHAGEMID VECTOR          COMPRISING SAID ANTIBODY PHAGE DISPLAY LIBRARY <140> 10-2008-0034516 <141> 2008-04-15 <160> 4 <170> KopatentIn 1.71 <210> 1 <211> 726 <212> DNA <213> Artificial Sequence <220> <223> AE sub-library <400> 1 gaggtgcagc tgttggagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc 60 tcctgtgcag cctctggatt cacctttagc rrttatkmta tgagctgggt ccgccaggct 120 ccagggaagg ggctggagtg ggtctcakbg atctmtymtr rtrrtrgtar tahatattac 180 gctgattctg taaaaggtcg gttcaccatc tccagagaca attccaagaa cacgctgtat 240 ctgcaaatga acagcctgag agccgaggac acggccgtgt attactgtgc garannknnk 300 nnknnkttcg actactgggg ccagggtaca ctggtcaccg tgagctcagg tggaggcggt 360 tcaggcggag gtggatccgg cggtggcgga tcgcagtctg tgctgactca gccaccctca 420 gcgtctggga cccccgggca gagggtcacc atctcttgta stggctcttc atctaatatt 480 ggcartaatd mtgtcwmctg gtaccagcag ctcccaggaa cggcccccaa actcctcatc 540 tatkmtrata rtmakcggcc aagcggggtc cctgaccgat tctctggctc caagtctggc 600 acctcagcct ccctggccat cagtgggctc cggtccgagg atgaggctga ttattactgt 660 gstdcttggg atkmtagcct gartgsttat gtcttcggcg gaggcaccaa gctgacggtc 720 ctgggt 726 <210> 2 <211> 741 <212> DNA <213> Artificial Sequence <220> <223> BE sub-library <400> 2 gaggtgcagc tgttggagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc 60 tcctgtgcag cctctggatt cacctttagc rrttatkmta tgagctgggt ccgccaggct 120 ccagggaagg ggctggagtg ggtctcakbg atctmtymtr rtrrtrgtar tahatattac 180 gctgattctg taaaaggtcg gttcaccatc tccagagaca attccaagaa cacgctgtat 240 ctgcaaatga acagcctgag agccgaggac acggccgtgt attactgtgc garagrtsbt 300 nnknnknnkn nknnknnknn kttcgactac tggggccagg gtacactggt caccgtgagc 360 tcaggtggag gcggttcagg cggaggtgga tccggcggtg gcggatcgca gtctgtgctg 420 actcagccac cctcagcgtc tgggaccccc gggcagaggg tcaccatctc ttgtastggc 480 tcttcatcta atattggcar taatdmtgtc wmctggtacc agcagctccc aggaacggcc 540 cccaaactcc tcatctatkm tratartmak cggccaagcg gggtccctga ccgattctct 600 ggctccaagt ctggcacctc agcctccctg gccatcagtg ggctccggtc cgaggatgag 660 gctgattatt actgtgstdc ttgggatkmt agcctgartg sttatgtctt cggcggaggc 720 accaagctga cggtcctggg t 741 <210> 3 <211> 759 <212> DNA <213> Artificial Sequence <220> <223> CF sub-library <400> 3 gaggtgcagc tgttggagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc 60 tcctgtgcag cctctggatt cacctttagc rrttatkmta tgagctgggt ccgccaggct 120 ccagggaagg ggctggagtg ggtctcakbg atctmtymtr rtrrtrgtar tahatattac 180 gctgattctg taaaaggtcg gttcaccatc tccagagaca attccaagaa cacgctgtat 240 ctgcaaatga acagcctgag agccgaggac acggccgtgt attactgtgc garabntvbt 300 vktnnknnkn nknnknnknn knnktmttmt kmtdatgsta tggacgtctg gggccagggt 360 acactggtca ccgtgagctc aggtggaggc ggttcaggcg gaggtggatc cggcggtggc 420 ggatcgcagt ctgtgctgac tcagccaccc tcagcgtctg ggacccccgg gcagagggtc 480 accatctctt gtastggctc ttcatctaat attggcarta atdmtgtcwm ctggtaccag 540 cagctcccag gaacggcccc caaactcctc atctatkmtr atartmakcg gccaagcggg 600 gtccctgacc gattctctgg ctccaagtct ggcacctcag cctccctggc catcagtggg 660 ctccggtccg aggatgaggc tgattattac tgtgstdctt gggatkmtag cctgartgst 720 tatgtcttcg gcggaggcac caagctgacg gtcctgggt 759 <210> 4 <211> 759 <212> DNA <213> Artificial Sequence <220> <223> DF sub-library <400> 4 gaggtgcagc tgttggagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc 60 tcctgtgcag cctctggatt cacctttagc rrttatkmta tgagctgggt ccgccaggct 120 ccagggaagg ggctggagtg ggtctcakbg atctmtymtr rtrrtrgtar tahatattac 180 gctgattctg taaaaggtcg gttcaccatc tccagagaca attccaagaa cacgctgtat 240 ctgcaaatga acagcctgag agccgaggac acggccgtgt attactgtgc garagntvbt 300 vktnnktgtn nknnknnknn ktgttmttmt kmtdatgsta tggacgtctg gggccagggt 360 acactggtca ccgtgagctc aggtggaggc ggttcaggcg gaggtggatc cggcggtggc 420 ggatcgcagt ctgtgctgac tcagccaccc tcagcgtctg ggacccccgg gcagagggtc 480 accatctctt gtastggctc ttcatctaat attggcarta atdmtgtcwm ctggtaccag 540 cagctcccag gaacggcccc caaactcctc atctatkmtr atartmakcg gccaagcggg 600 gtccctgacc gattctctgg ctccaagtct ggcacctcag cctccctggc catcagtggg 660 ctccggtccg aggatgaggc tgattattac tgtgstdctt gggatkmtag cctgartgst 720 tatgtcttcg gcggaggcac caagctgacg gtcctgggt 759  

Claims (6)

In a method for preparing an antibody phage surface presentation library which provides artificial diversity to complementarity determining regions (CDRs) using the V _H 3-23 / V _L 1g gene as a skeleton, Iii) introducing restriction enzyme cleavage sequences immediately after the leader sequence of the beta lactamase gene in the plasmid vector having the beta lactamase gene as a selection marker to prepare a pFDV plasmid vector having the cleavage map as shown in FIG. 3; Ii) cleaving a pFDV plasmid vector using said restriction enzyme; Iii) single chain fragment antibody (scFv) gene consisting of AE, BE, CF and DF sublibrary, which is obtained through chain polymerization between the cleaved pFDV vectors as shown in Table 2 and each has the nucleotide sequence or amino acid sequence of FIG. Inserting a library; Iii) transforming the pFDV vector containing the scFv gene library into a host strain and culturing in a medium containing antibiotics; Iii) separating and purifying the pFDV plasmid vector containing the scFv gene library after culture; Iii) grafting CDR-H3 through a polymerase chain reaction with primer pairs of the oligonucleotides of Table 1 using the pFDV plasmid vector containing the purified scFv gene library as a template; Iii) a method for producing an antibody phage surface presentation library comprising cutting and ligating the scFv library gene and pComb3X vector transplanted with the CDR-H3 with restriction enzymes and transforming and culturing the host strain. The method of claim 1, The restriction enzyme is SfiI antibody phage surface presentation library manufacturing method, characterized in that. The method of claim 1, The plasmid vector having the beta lactamase gene as a selection marker is a pET17b plasmid vector. An antibody phage surface presentation library prepared by the method for producing an antibody phage surface presentation library of any one of claims 1 to 3. A phagemid vector combination in which a pComb3X vector is inserted with a scFv gene library consisting of AE, BE, CF, and DF sublibrary each having the nucleotide sequence or amino acid sequence of FIG. 2. Bacteriophage (accession number: KCCM10938P) containing a phagemid vector into which a pComb3X vector is inserted with a scFv gene library consisting of AE, BE, CF and DF sublibrary each having the nucleotide sequence or amino acid sequence of FIG. 2.

Images